Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC

被引：0
|
作者：
Lee, Matthew
Miao, Emily
Zhang, Chenxin
Xue, Xiaonan
Tuckman, Steven
Halmos, Balazs
Cheng, Haiying
机构：
[1] Montefiore Einstein Canc Ctr, Bronx, NY USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Montefiore Pharm Dept, Bronx, NY USA
[4] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18536
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC
    Lee, M.
    Miao, E.
    Zhang, C.
    Xue, X.
    Tuckman, S.
    Halmos, B.
    Cheng, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S331 - S332
  • [2] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [3] Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Batra, Ullas
    Do, Kien
    Sitthideatphaiboon, Piyada
    Danchaivijitr, Pongwut
    Lee, Kang-Yun
    Chindaprasirt, Jarin
    Yang, Cheng-Ta
    Chang, Gee-Chen
    Charoentum, Chaiyut
    Ungtrakul, Teerapat
    Moran, Juan Ignacio Hernandez
    Hartmaier, Ryan
    Haskins, Matthew
    Xu, Wanning
    Riess, Jonathan W.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [4] Clinical efficacy of frontline immunotherapy (IO) in ethnic-minority patients (pts) with metastatic NSCLC
    Lee, Matthew
    Liu, Jianyou
    Miao, Emily
    Wang, Shuai
    Zhang, Frank
    Wei, John X.
    Chung, Julie
    Xue, Xiaonan
    Halmos, Balazs
    Hosgood, Dean
    Cheng, Haiying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [6] Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis
    Fan, Y.
    Wu, H.
    Chen, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [7] Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC
    Rubio, Jaime
    Santolaya, Carlota
    Fernandez, Marina
    Villalba, Paula Lucia
    Avedillo, Mercedes
    Garcia-Foncillas, Jesus
    Domine, Manuel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    [J]. Advances in Therapy, 2023, 40 : 4545 - 4560
  • [9] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hayashi, Hidetoshi
    Nishio, Makoto
    Takahashi, Michiko
    Tsuchiya, Hiroaki
    Kasahara-Kiritani, Mami
    [J]. ADVANCES IN THERAPY, 2023, 40 (10) : 4545 - 4560
  • [10] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
12345